Figure e-3. Control antigen-specific antibodies in CSF and serum before (V0) and after 12 months of natalizumab treatment (V12). Serum and CSF levels of antibodies reactive to (A) mumps virus, (B) influenza A virus, (C) influenza B virus, (D) enterovirus, (E) tetanus toxoid, (F) diphtheria toxoid, (G) H. pylori and (H) C. pneumoniae (C. pneu.) are depicted in arbitrary units (AU). Intrathecal production of the respective antibodies is indicated by CSF/serum antigen-specific antibody index (CAI Mumps, CAI Influenza A, CAI Influenza B, CAI Enterovirus, CAI Tetanus, CAI Diphtheria, CAI H. pylori, CAI C. pneu.). The p-value is shown in case of statistically significant differences. Statistics: Wilcoxon-matched pairs test (A-H).